Company intelligence / Profile preview

Alphageneron Pharmaceuticals

Boston, Massachusetts, United Statesalphageneron.com ↗
Ownership
Private
Employees
~1
Development stage
Phase 2
01

Overview

Developing targeted NK cell therapies supported by Companion Diagnostics. Multiple programs in preclinical and discovery stages, with no active clinical trials found on ClinicalTrials.gov.

Therapeutic areas
Oncology
Modalities
Natural Killer (NK) cell therapiesAntibody Drug Conjugates (ADCs)CAR-NK cell therapies
Industry
Biotech
02

Drug pipeline

4 assets

AP-161

Preclinical

3 more assets in the full pipeline.

Beyond the preview

Go deeper on Alphageneron Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alphageneron Pharmaceuticals.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call